Article révisé par les pairs
Titre:
  • Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
Auteur:Beck, Joseph Thaddeus; Hortobagyi, Gabriel N.; Campone, Mario; Lebrun, Fabienne; Piccart-Gebhart, Martine; Deleu, Ines; Rugo, Hope; Pistilli, Barbara; Masuda, Norikazu; Hart, Lowell L.L.; Melichar, Bohuslav; Dakhil, Shaker; Geberth, Matthias; Nunzi, Martina; Heng, Daniel Y C; Brechenmacher, Thomas; El-Hashimy, Mona; Douma, Shyanne; Ringeisen, François
Informations sur la publication:Breast cancer research and treatment, 143, 3, page (459-467)
Statut de publication:Publié, 2014-02
Sujet CREF:Cancérologie
Mots-clés:BOLERO-2
Breast cancer
Everolimus
First-line therapy
Metastatic disease
mTOR inhibition
MeSH keywords:Aged
Aged, 80 and over
Androstadienes -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Breast Neoplasms -- drug therapy -- genetics -- pathology
Clinical Trials as Topic
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local -- drug therapy -- pathology
Neoplasms, Hormone-Dependent -- drug therapy -- genetics -- pathology
Receptors, Estrogen -- genetics
Receptors, Progesterone -- genetics
Sirolimus -- administration & dosage -- analogs & derivatives
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0167-6806
info:doi/10.1007/s10549-013-2814-5
info:scp/84894045903
info:pmid/24362951
PMC3907668

Documents en relation

DI-fusion